Our recent activity
Medasense selected as one of “Fierce 15 Medtech Companies of 2022”
As the opioid epidemic exacerbates the complex field of pain management, Israel’s Medasense Biometrics is on a mission to quantify and personalize patient suffering.
At the heart of that quest is the company’s artificial-intelligence-powered patient monitor designed to track nociception, or the physiological response to pain. Dubbed PMD-200, the monitor comes equipped with Medasense’s own alchemy of nociception level (NOL) technology designed to objectively quantify a patients pain response, in turn allowing healthcare professionals to provide bespoke pain treatment.
What makes Medasense fierce: Medasense won FDA marketing authorization for its technology in February through its de novo premarket review pathway.
The technology has been leveraged for much longer in Europe, where PMD-200 scored a CE mark back in 2017. There, Medasense’s platform is largely distributed by Medtronic, which covers deals in the U.K., France, Spain and Portugal, Italy, Greece, Germany, Austria, Switzerland and various Nordic countries.
Asabys Partners Leads €10 Million Extension of SafeHeal’s Oversubscribed Series C Financing to Accelerate Commercialization of Colovac®
Asabys Partners Leads €10 Million Extension of SafeHeal’s Oversubscribed Series C Financing to Accelerate Commercialization of Colovac®
SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines
SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines
Deepull secures oversubscribed €50 million Series C financing to advance UllCORE diagnostic system for direct-from-blood rapid pathogen detection